BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, Greco MR, Alfarouk KO, Cardone RA. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers (Basel) 2022;14:2486. [PMID: 35626089 DOI: 10.3390/cancers14102486] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang W, Li X, Xiang C, Zhou W. Neutrophils in pancreatic cancer: Potential therapeutic targets. Front Oncol 2022;12:1025805. [DOI: 10.3389/fonc.2022.1025805] [Reference Citation Analysis]
2 Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules 2022;12:1450. [PMID: 36291659 DOI: 10.3390/biom12101450] [Reference Citation Analysis]
3 Wu L, Ge Y, Yuan Y, Li H, Sun H, Xu C, Wang Y, Zhao T, Wang X, Liu J, Gao S, Chang A, Hao J, Huang C. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Cancer Lett 2022;:215864. [PMID: 35981571 DOI: 10.1016/j.canlet.2022.215864] [Reference Citation Analysis]